Qynapse
Company Details
Status: Private
Employees: 11-50
Location:
130 rue de Lourmel, Paris, 75015, FR
Type:
sample
sample
sample
Technology:
sample
sample
About: Qynapse is a neuroimaging technology company founded in 2015, originating from the CATI consortium of neuroimaging research laboratories. Based in France, with offices in the U.S. and Canada, Qynapse is dedicated to enhancing the diagnosis and monitoring of central nervous system (CNS) disorders, including Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease. The company focuses on improving accuracy and reliability in clinical and research environments through AI-driven solutions.
Qynapse offers proprietary AI-powered tools for analyzing neuroimaging data, such as MRI and PET scans. Its key product, QyScore®, features an automated platform with 20 algorithms and over 200 measures for assessing neurodegeneration and neuroinflammation. The company also provides clinical trial solutions that significantly reduce image-reading variability, enhancing trial efficiency, and normative datasets that deliver precise imaging metrics for tracking disease progression. Qynapse serves pharmaceutical and biotech companies, healthcare providers, and researchers, aiming to improve patient outcomes and accelerate drug development timelines.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Qynapse | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.